Showing results (101-110 of 200) with videos related to

Sort By:
Pageof 20
Cancer Research|April 3, 2008
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activityBohua Li, Shu Shi, Weizhu Qian, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|June 15, 2013
Single segment of posterior lumbar interbody fusion for adult isthmic spondylolisthesis: reduction or fusion in situXiao-Feng Lian, Tie-Sheng Hou, Jian-Guang Xu, et al.
Mabs|February 14, 2012
Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjectsBo Zhou, Birong Lin, Jing Li, et al.
Mabs|January 14, 2016
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacyYun Yang, Qingcheng Guo, Xi Chen, et al.
Molecular Immunology|July 9, 2011
Clearance of Propionibacterium acnes by kupffer cells is regulated by osteopontin through modulating the expression of p47phoxHaiou Yang, Huaizu Guo, Kexing Fan, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|November 6, 2010
An MRI study of psoas major and abdominal large vessels with respect to the X/DLIF approachWan-Kun Hu, Shi-Sheng He, Shao-Cheng Zhang, et al.
Analytical Biochemistry|September 14, 2021
N-Glycosylation and enzymatic activity of the rHuPH20 expressed in Chinese hamster ovary cellsTao Liu, Yantao Li, Jin Xu, et al.
Biochemical and Biophysical Research Communications|April 25, 2007
Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibodyBohua Li, Hao Wang, Dapeng Zhang, et al.
The Journal of Biological Chemistry|March 19, 2013
Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximabShuaiyi Liang, Jianxin Dai, Sheng Hou, et al.
Clinical Pharmacology in Drug Development|July 2, 2022
A Randomized, Double-Blind, Parallel Controlled, Single-Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male SubjectsRuirui Zhou, Qian Chen, Sheng Hou, et al.
Pageof 20